Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Travere Therapeutics
TVTX
Travere Therapeutics
Regulatory Pressures And Competition Will Hamper Uptake But Hope Endures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
23 Aug 25
Updated
23 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$20.00
10.4% undervalued
intrinsic discount
23 Aug
US$17.92
Loading
1Y
98.0%
7D
-4.5%
Author's Valuation
US$20.0
10.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$20.0
10.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-373m
710m
2014
2017
2020
2023
2025
2026
2028
Revenue US$710.0m
Earnings US$32.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
25.00%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.05%
Calculation
US$32.41m
Earnings '28
x
82.44x
PE Ratio '28
=
US$2.67b
Market Cap '28
US$2.67b
Market Cap '28
/
109.20m
No. shares '28
=
US$24.47
Share Price '28
US$24.47
Share Price '28
Discounted to 2025 @ 7.02% p.a.
=
US$19.96
Fair Value '25